Cellectar Biosciences (CLRB) director awarded 25,000 options at $2.70 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock. The options were awarded at an exercise price of $2.70 per share and expire on July 7, 2036. Following this grant, he holds options for 25,000 shares.
According to the footnote, the option vests in full on July 7, 2027, subject to his continued service through that vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
NEIS JOHN
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 25,000 options
Exercise price: $2.70 per share
Post-grant option holdings: 25,000 options
+2 more
5 metrics
Options granted
25,000 options
Stock option grant to director John Neis
Exercise price
$2.70 per share
Strike price of stock option grant
Post-grant option holdings
25,000 options
Total options held following transaction
Vesting date
July 7, 2027
Options vest in full on this date
Expiration date
July 7, 2036
Option term end date
Key Terms
Stock option (right to buy), Grant, award, or other acquisition, exercise price, vesting date, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 2.7000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting date financial
"shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date"
expiration date financial
"expiration_date: 2036-07-07T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Cellectar Biosciences (CLRB) director John Neis report on this Form 4?
Director John Neis reported receiving a grant of stock options for 25,000 Cellectar Biosciences shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.
How many Cellectar Biosciences (CLRB) options were granted to John Neis and at what price?
John Neis was granted stock options covering 25,000 Cellectar Biosciences shares at an exercise price of $2.70 per share. This grant provides potential future ownership if exercised at or above that strike price.
When do John Neis’s Cellectar Biosciences (CLRB) stock options vest and expire?
The stock options granted to John Neis vest in full on July 7, 2027, subject to his continued service. The options have an expiration date of July 7, 2036, giving him a long window to exercise after vesting.
Is the Cellectar Biosciences (CLRB) Form 4 for an open-market trade or an option grant?
The Form 4 reports an option grant, not an open-market trade. The transaction uses code “A” for a grant or award acquisition of 25,000 stock options, representing compensation rather than a market purchase or sale of existing shares.
How many Cellectar Biosciences (CLRB) options does John Neis hold after this transaction?
After this transaction, John Neis holds stock options for 25,000 Cellectar Biosciences common shares directly. The filing does not list other derivative holdings, so this grant represents his reported option position in this specific Form 4.